4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $117,720.00 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

4D Molecular Therapeutics Stock Down 0.9%

Shares of FDMT traded down $0.10 during trading hours on Thursday, reaching $11.52. 984,926 shares of the company traded hands, compared to its average volume of 788,707. The business has a fifty day moving average price of $9.50 and a 200-day moving average price of $9.13. 4D Molecular Therapeutics, Inc. has a 12-month low of $3.68 and a 12-month high of $12.34. The stock has a market capitalization of $602.27 million, a P/E ratio of -4.48 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. As a group, research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently made changes to their positions in the company. Sei Investments Co. increased its holdings in shares of 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after purchasing an additional 1,050 shares in the last quarter. Martingale Asset Management L P boosted its holdings in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after buying an additional 1,303 shares in the last quarter. Dimensional Fund Advisors LP grew its position in 4D Molecular Therapeutics by 3.7% during the third quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock valued at $504,000 after buying an additional 2,069 shares during the period. Russell Investments Group Ltd. grew its position in 4D Molecular Therapeutics by 11.7% during the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after buying an additional 2,284 shares during the period. Finally, Prelude Capital Management LLC increased its holdings in 4D Molecular Therapeutics by 11.1% in the third quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after buying an additional 2,300 shares in the last quarter. 99.27% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on FDMT. Chardan Capital reiterated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, March 19th. Jefferies Financial Group restated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.88.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.